Comments on "Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines"
- PMID: 37054478
- PMCID: PMC10123133
- DOI: 10.1016/j.esmoop.2023.101212
Comments on "Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines"
Conflict of interest statement
The authors have declared no conflicts of interest.
Comment on
-
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.ESMO Open. 2023 Feb;8(1):100604. doi: 10.1016/j.esmoop.2022.100604. Epub 2022 Nov 14. ESMO Open. 2023. PMID: 36870739 Free PMC article. Review.
References
-
- Catalan Institute of Oncology. Drug policy. Available at https://ico.gencat.cat/ca/professionals/politica_del_medicament/index.ht.... Accessed April 1, 2023.
-
- Ministerio de Sanidad y Política Social. Boletín Oficial del Estado. Real Decreto 1015/2009, de 19 junio, por el que se regula la disponibilidad de medicamentos en situacions especiales. Available at https://www.boe.es/eli/es/rd/2009/06/19/1015. Accessed April 1, 2023.
-
- Jordán de Luna C., Fernández E., Mesía R., Clopés A. Clinical practice guidelines for the optimization of hemato-oncological care: the ICOPraxis. Clin Transl Oncol. 2023;25(2):555–559. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical